Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: Findings from a national health plan

Current Medical Research and Opinion

Volumn 31, Issue 8, 2015, Pages 1495-1500

  Huang, Xingyue ^a   Liu, Zhiwen ^a   Shankar, Ravi R ^a   Rajpathak, Swapnil ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cost sharing; Diabetes mellitus; DPP 4 inhibitors; Drug utilization; Managed care programs; Pharmacy formulary

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN DERIVATIVE; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; MEGLITINIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG COST; DRUG FORMULARY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PUBLIC HEALTH; TREATMENT DURATION; TREATMENT INDICATION; AGED; DIABETES MELLITUS, TYPE 2; MEDICINAL CHEMISTRY; MIDDLE AGED;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; SITAGLIPTIN PHOSPHATE;

EID: 84940666549     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1060211     Document Type: Article

References (24)

1. Hoadley J. Cost containment strategies for prescription drugs: assessing the evidence in the literature. Kaiser Family Foundation, 2005. Available at: https://kaiserfamilyfoundation. files. wordpress. com/2013/01/costcontainment-strategies-for-precription-drugs-assessing-the-evidence-inthe-literature-report. pdf
2. The Kaiser Family Foundation and HRET (Health Research and Educational Trust). Employer Health Benefits 2014 Annual Survey. 2014. Available at: http://files. kff. org/attachment/2014-employer-health-benefits-surveyfull-report. Accessed March 2015
3. Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity Evidence from high-income countries. Int J Equity Health 2008;7:12
4. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Therapeut 2003;25:3147-61; discussion 4-6
5. Rector TS, Finch MD, Danzon PM, et al. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care 2003;41:398-406
6. Nair KV, Wolfe P, Valuck RJ, et al. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. JMCP 2003;9:123-33
7. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. New Engl J Med 2003;349:2224-32
8. Hodgkin D, Parks Thomas C, Simoni-Wastila L, et al. The effect of a three-tier formulary on antidepressant utilization and expenditures. j Ment Health Policy Econ 2008;11:67-77
9. Gleason PP, Gunderson BW, Gericke KR. Are incentive-based formularies inversely associated with drug utilization in managed care? Ann Pharmacother 2005;39:339-45
10. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298:61-9
11. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005; 11:730-40
12. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-50
13. Mann BS, Barnieh L, Tang K, et al. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. PloS One 2014;9:e89168
14. Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane database System Rev 2008;(1):CD007017
15. CDC. 2014 National Diabetes Fact Sheet. Atlanta, GA: CDC, 2014
16. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health affairs (Project Hope). 2004;(Suppl Web Exclusives):W4-455-68. doi: 10. 1377/hlthaff. w4. 455
17. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care 2005;43:951-9
18. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occupat Environ Med Am Coll Occupat Environl Med 2008;50:535-41
19. Sacks NC, Burgess Jr JF, Cabral HJ, et al. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 2013;28:876-85
20. Bridge to Data: Optum Insights Clinformatics Data Mart. 2015. Available at: http://www. bridgetodata. org. Accessed March 20, 2015
21. Kleinrock M. The use of medicines in the United States: Review of 2011. New Jersey: IMS Institute for Healthcare Informatics, 2012. Available at: http://www. imshealth. com/deployedfiles/imshealth/Global/Content/IMS%20 Institute/Static%20File/IHII-UseOfMed-report. pdf
22. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9
23. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-34
24. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005;11(Suppl 5):S170-6